

Supplementary Table 1A. Factors associated with objective response of Child-Pugh A cases

Factor		multivariable analysis		
		Odds Ratio	95%C.I.	P value
Age (years)	≤ 71	1.65	0.64-4.24	0.30
Sex	Male	0.95	0.33-2.72	0.93
HCV Status	Positive	0.74	0.28-1.94	0.53
BMI (kg/m ²)	≤ 23.2	0.52	0.21-1.26	0.148
Child-Pugh score	5 (vs.6)	1.58	0.64-3.92	0.33
PS	0 (vs.1, 2)	3.72	0.93-15.00	0.064
BCLC stage	B (vs. C)	1.12	0.44-2.83	0.82
Past history of TKI	experienced	1.43	0.37-5.55	0.61
Past history of TACE	experienced	0.67	0.21-2.08	0.48
AFP (ng/mL)	≤ 69.3	0.84	0.34-2.05	0.69
DCP (mAU/mL)	≤ 772	2.70	1.02-7.13	0.045
RDI	≥ 0.70	2.28	0.93-5.58	0.072

HCV, hepatitis C virus; BMI, Body Mass Index; PS, Eastern Cooperative Oncology Group performance status; BCLC, Barcelona clinic liver cancer; TKI, tyrosine kinase inhibitor; TACE, transcatheter arterial chemoembolization; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; RDI, relative dose intensity

Supplementary Table 1B. Factors associated with objective response of Child-Pugh B cases

Factor		Multivariable analysis		
		Odds Ratio	95%C.I.	P value
Age (years)	≤ 71	0.74	0.12-4.77	0.75
Child-Pugh score	7 (vs.8)	3.52	0.32-38.30	0.30
PS	0 (vs.1, 2)	3.27	0.29-36.70	0.34
BCLC stage	B (vs. C)	3.58	0.66-19.40	0.139
RDI	≥ 0.70	1.88	0.22-16.00	0.56

HCV, hepatitis C virus; PS, Eastern Cooperative Oncology Group performance status; BCLC, Barcelona clinic liver cancer; RDI, relative dose intensity

Supplementary Table 2A. Factors associated with Overall survival time of Child-Pugh A cases

Factor		Multivariable analysis		
		HR	95%C.I.	P value
Age (years)	≤ 71	0.66	0.31-1.37	0.26
Child-Pugh score	5 (vs.6)	0.66	0.32-1.34	0.26
BCLC stage	B (vs. C)	0.43	0.20-0.93	0.032

HR, hazard ratio; BCLC, Barcelona clinic liver cancer

Supplementary Table 2B. Factors associated with Overall survival time of Child-Pugh B cases

Factor		Multivariable analysis		
		HR	95%C.I.	P value
Child-Pugh score	7 (vs.8)	0.44	0.19-1.04	0.061
BCLC stage	B (vs. C)	0.27	0.10-0.69	0.006

HR, hazard ratio; BCLC, Barcelona clinic liver cancer


Supplementary Table 3. Treatment after lenvatinib therapy

	CP-A (n=77)		CP-B (n=35)	
sorafenib	11	(14.3%)	3	(8.6%)
regorafenib	2	(2.6%)	0	(0.0%)
HAIC	4	(5.2%)	2	(5.7%)
Critical trial	2	(2.6%)	0	(0.0%)
Lenvatinib beyond PD	21	(27.3%)	8	(22.9%)
TACE	4	(5.2%)	1	(2.9%)
BSC	33	(42.9%)	21	(60.0%)

All values are expressed as the number (%)

CP-A, Child-Pugh grade A; CP-B, Child-Pugh grade B; HAIC, hepatic arterial infusion chemotherapy; PD, Progressive disease; TACE, transcatheter arterial chemoembolization; BSC; Best supportive care

Supplementary Figure 1.



Supplementary Figure 2.

